TITLE

Growth Hormone Release Inhibiting Hormone in Acromegaly

AUTHOR(S)
Besser, G. M.; Mortimer, C. H.; Carr, D.; Schally, A. V.; Coy, D. H.; Evered, D.; Kastin, A. J.; Tunbridge, W. M. G.; Thorner, M. O.; Hall, R.
PUB. DATE
March 1974
SOURCE
British Medical Journal;3/2/1974, Vol. 1 Issue 5904, p352
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
64109696

 

Related Articles

  • Long term treatment of acromegaly with a long acting analogue of somatostatin. Ch'ng, L.J.C.; Sandler, L.M.; Kraenzlin, M.E.; Burrin, J.M.; Joplin, G.F.; Bloom, S.R. // British Medical Journal (Clinical Research Edition);1/26/1985, Vol. 290 Issue 6464, p284 

    Examines the long term treatment of acromegaly using somatostatin. Inhibition of secretion of growth hormone in patients with acromegaly; Relation between active acromegaly and increase morbidity and mortality; Concentrations of growth hormone before and following the treatment with selective...

  • acromegaly.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p34 

    An encyclopedia entry for "acromegaly," which is a syndrome of excessive secretion of growth hormone, is presented.

  • Section II hormonal causes. Sotos, Juan F. // Clinical Pediatrics;Nov1996, Vol. 35 Issue 11, p579 

    Focuses on excessive secretion of growth hormones. Pituitary gigantism and acromegaly; Manifestations in gigantism and acromegaly.

  • Acromegaly: treatment after 100 years. Wass, J.A.H. // BMJ: British Medical Journal (International Edition);12/11/93, Vol. 307 Issue 6918, p1505 

    Comments on the treatment of acromegaly. Increase in the morbidity and mortality among patients with acromegaly; Aims of the treatment; Concentration of growth hormones.

  • Abnormalities of growth hormone release in response to human pancreatic growth hormone releasing factor (GRF (1-44)) in acromegaly and hypopituitarism. Wood, S.M.; Ch'ng, J.C.L.; Adams, E.F.; Webster, J.D.; Joplin, G.F.; Mashiter, K.; Bloom, S.R. // British Medical Journal (Clinical Research Edition);5/28/1983, Vol. 286 Issue 6379, p1687 

    Examines the effects of human pancreatic growth hormone releasing factor [GRF [1-44]] to growth hormone release in patients with hypopituitarism and acromegaly. Clinical and biochemical features of patients with acromegaly; Characteristics of patients with impaired pituitary function; Use of...

  • Circulating growth hormone releasing factor concentrations in normal subjects and patients with acromegaly. Penny, Elizabeth S.; Penman, Erica; Price, Janet; Rees, Lesley H.; Sopwith, A.M.; Wass, J.A.H.; Lytras, N.; Besser, G.M. // British Medical Journal (Clinical Research Edition);8/25/1984, Vol. 289 Issue 6443, p453 

    Examines the circulating growth hormone releasing factor (GRF) concentrations in patients with and without acromegaly in Great Britain. Measurement by radioimmunoassay; Evaluation of GRF concentrations in plasma samples;.

  • Modern treatment of acromegaly. Merza, Z. // Postgraduate Medical Journal;Apr2003, Vol. 79 Issue 930, p189 

    Acromegaly is an endocrine disorder characterised by increased morbidity and mortality. It is usually caused by a growth hormone secreting pituitary adenoma and is manifested by a variety of clinical features. Surgery is usually the treatment of choice, however over the last few years, several...

  • Too stressed to grow.  // Joe Weider's Muscle & Fitness;Feb95, Vol. 56 Issue 2, p26 

    Reports on the possibility that the stress hormone cortisol inhibits growth hormone release. Effect of depression; Insight on testing procedure.

  • Effect of high dose somatostatin analogue on growth hormone concentrations in acromegaly. Sandler, L.M.; Burrin, J.M.; Joplin, G.F.; Bloom, S.R. // British Medical Journal (Clinical Research Edition);3/12/1988, Vol. 296 Issue 6624, p751 

    Investigates the biochemical effects of increasing doses of octreotide in patients with acromegaly. Administration of octreotide in patient with active acromegaly; Decrease in growth hormone and insulin concentrations; Normalization of growth hormone concentration by subcutaneous octreotide.

  • Long-term treatment of acromegaly with bromocriptine. Wass, J.A.H.; Thorner, M.O.; Morris, D.V.; Rees, Lesley H.; Mason, A. Stuart; Jones, A.E.; Besser, G.M. // British Medical Journal;4/2/1977, Vol. 1 Issue 6065, p875 

    Examines the effectiveness of bromocriptine on the log-term treatment of acromegaly. Decline of the mean circulating growth hormones; Suppression of the growth hormone during the long-term management of acromegaly; Side effects of bromocriptine.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics